Soluble epoxide hydrolase inhibitor attenuates inflammation and airway hyperresponsiveness in mice

American Journal of Respiratory Cell and Molecular Biology

Volumn 52, Issue 1, 2015, Pages 46-55

  Yang, Jun ^a   Bratt, Jennifer ^b   Franzi, Lisa ^b   Liu, Jun Yan ^a   Zhang, Guodong ^a   Zeki, Amir A ^b   Vogel, Christoph F A ^a   Williams, Keisha ^b   Dong, Hua ^a   Lin, Yanping ^a   Hwang, Sung Hee ^a   Kenyon, Nicholas J ^b   Hammock, Bruce D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Asthma; Inflammation; Lipid mediators; Soluble epoxide hydrolase; Type 2 T helper cell cytokines

Indexed keywords

ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; DOCOSAHEXAENOIC ACID; EOTAXIN; EPOXIDE HYDROLASE; HYDROLASE INHIBITOR; INTERLEUKIN 4; INTERLEUKIN 5; NITRIC OXIDE; OVALBUMIN; PROSTAGLANDIN E3; PROSTAGLANDIN F1 ALPHA; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN J2; RANTES; THROMBOXANE B2; TRANS 4 [4 [3 (4 TRIFLUOROMETHOXYPHENYL)UREIDO]CYCLOHEXYLOXY]BENZOIC ACID; UNCLASSIFIED DRUG; ARACHIDIC ACID; AUTACOID; CYTOKINE; ENZYME INHIBITOR; EPHX2 PROTEIN, MOUSE;

ALLERGIC AIRWAY INFLAMMATION; ALLERGIC ASTHMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL INFILTRATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME INHIBITION; EOSINOPHIL COUNT; IC50; LIQUID CHROMATOGRAPHY; LUNG COMPLIANCE; LUNG LAVAGE; LUNG PARENCHYMA; LUNG RESISTANCE; MALE; MOUSE; NONHUMAN; RESPIRATORY TRACT ALLERGY; TANDEM MASS SPECTROMETRY; TH2 CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; ASTHMA; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; GENETICS; INFLAMMATION; METABOLISM; MORTALITY; PATHOLOGY; VASCULAR RESISTANCE;

MURINAE; MUS;

ANIMALS; ASTHMA; CYTOKINES; DISEASE MODELS, ANIMAL; EICOSANOIC ACIDS; ENZYME INHIBITORS; EPOXIDE HYDROLASES; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MICE; TH2 CELLS; VASCULAR RESISTANCE;

EID: 84920266520     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2013-0440OC     Document Type: Article

References (42)

1. Masoli M, Fabian D, Holt S, Beasley R; Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004;59:469-478.
2. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012;18:716-725.
3. Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol 2008;8:218-230.
4. Morisseau C, Hammock BD. Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health. Annu Rev Pharmacol Toxicol 2013;53:37-58.
5. Kersting U, Kersting D, Spring KR. Ketoconazole activates Clconductance and blocks Cl- and fluid absorption by cultured cystic fibrosis (CFPAC-1) cells. Proc Natl Acad Sci USA 1993;90:4047-4051.
6. Pascual JM, McKenzie A, Yankaskas JR, Falck JR, Zeldin DC. Epoxygenase metabolites of arachidonic acid affect electrophysiologic properties of rat tracheal epithelial cells1. J Pharmacol Exp Ther 1998;286:772-779.
7. Salvail D, Dumoulin M, Rousseau E. Direct modulation of tracheal Clchannel activity by 5,6- and 11,12-EET. Am J Physiol 1998;275:L432-L441.
8. Zeldin DC, Plitman JD, Kobayashi J, Miller RF, Snapper JR, Falck JR, Szarek JL, Philpot RM, Capdevila JH. The rabbit pulmonary cytochrome P450 arachidonic acid metabolic pathway: characterization and significance. J Clin Invest 1995;95:2150-2160.
9. Smith KR, Pinkerton KE, Watanabe T, Pedersen TL, Ma SJ, Hammock BD. Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc Natl Acad Sci USA 2005;102:2186-2191.
10. Wang L, Yang J, Guo L, Uyeminami D, Dong H, Hammock BD, Pinkerton KE. Use of a soluble epoxide hydrolase inhibitor in smoke-induced chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2012;46:614-622.
11. Alvarez DF, Gjerde EA, Townsley MI. Role of EETs in regulation of endothelial permeability in rat lung. Am J Physiol Lung Cell Mol Physiol 2004;286:L445-L451.
12. Fleming I. Cytochrome P450-dependent eicosanoid production and crosstalk. Curr Opin Lipidol 2011;22:403-409.
13. Loot AE, Fleming I. Cytochrome P450-derived epoxyeicosatrienoic acids and pulmonary hypertension: central role of transient receptor potential C6 channels. J Cardiovasc Pharmacol 2011;57:140-147.
14. Shen HC, Hammock BD. Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications. J Med Chem 2012;55:1789-1808.
15. Rose TE, Morisseau C, Liu JY, Inceoglu B, Jones PD, Sanborn JR, Hammock BD. 1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain. J Med Chem 2010;53:7067-7075.
16. Kim IH, Tsai HJ, Nishi K, Kasagami T, Morisseau C, Hammock BD. 1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic properties. J Med Chem 2007;50:5217-5226.
17. Hwang SH, Tsai HJ, Liu JY, Morisseau C, Hammock BD. Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem 2007;50:3825-3840.
18. Xu D, Li N, He Y, Timofeyev V, Lu L, Tsai HJ, Kim IH, Tuteja D, Mateo RK, Singapuri A, et al. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci USA 2006;103:18733-18738.
19. Ai D, Fu Y, Guo D, Tanaka H, Wang N, Tang C, Hammock BD, Shyy JY, Zhu Y. Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc Natl Acad Sci USA 2007;104:9018-9023.
20. Ai D, Pang W, Li N, Xu M, Jones PD, Yang J, Zhang Y, Chiamvimonvat N, Shyy JY, Hammock BD, et al. Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy. Proc Natl Acad Sci USA 2009;106:564-569.
21. Liu JY, Yang J, Inceoglu B, Qiu H, Ulu A, Hwang SH, Chiamvimonvat N, Hammock BD. Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model. Biochem Pharmacol 2010;79:880-887.
22. Schmelzer KR, Kubala L, Newman JW, Kim IH, Eiserich JP, Hammock BD. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci USA 2005;102:9772-9777.
23. Inceoglu B, Jinks SL, Ulu A, Hegedus CM, Georgi K, Schmelzer KR, Wagner K, Jones PD, Morisseau C, Hammock BD. Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways. Proc Natl Acad Sci USA 2008;105:18901-18906.
24. Inceoglu B, Wagner K, Schebb NH, Morisseau C, Jinks SL, Ulu A, Hegedus C, Rose T, Brosnan R, Hammock BD. Analgesia mediated by soluble epoxide hydrolase inhibitors is dependent on cAMP. Proc Natl Acad Sci USA 2011;108:5093-5097.
25. Inceoglu B, Wagner KM, Yang J, Bettaieb A, Schebb NH, Hwang SH, Morisseau C, Haj FG, Hammock BD. Acute augmentation of epoxygenated fatty acid levels rapidly reduces pain-related behavior in a rat model of type I diabetes. Proc Natl Acad Sci USA 2012;109:11390-11395.
26. Keserü B, Barbosa-Sicard E, Schermuly RT, Tanaka H, Hammock BD, Weissmann N, Fisslthaler B, Fleming I. Hypoxia-induced pulmonary hypertension: comparison of soluble epoxide hydrolase deletion vs. inhibition. Cardiovasc Res 2010;85:232-240.
27. Revermann M, Barbosa-Sicard E, Dony E, Schermuly RT, Morisseau C, Geisslinger G, Fleming I, Hammock BD, Brandes RP. Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats. J Hypertens 2009;27:322-331.
28. Bratt JM, Franzi LM, Linderholm AL, Last MS, Kenyon NJ, Last JA. Arginase enzymes in isolated airways from normal and nitric oxide synthase 2-knockout mice exposed to ovalbumin. Toxicol Appl Pharmacol 2009;234:273-280.
29. Bratt JM, Williams K, Rabowsky MF, Last MS, Franzi LM, Last JA, Kenyon NJ. Nitric oxide synthase enzymes in the airways of mice exposed to ovalbumin: Nos2 expression is nos3 dependent. Mediators Inflam 2010;2010:1-15.
30. Yang J, Schmelzer K, Georgi K, Hammock BD. Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry. Anal Chem 2009;81:8085-8093.
31. Yamabayashi C, Koya T, Kagamu H, Kawakami H, Kimura Y, Furukawa T, Sakagami T, Hasegawa T, Sakai Y, Matsumoto K, et al. A novel prostacyclin agonist protects against airway hyperresponsiveness and remodeling in mice. Am J Respir Cell Mol Biol 2012;47:170-177.
32. Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 2009;8:794-805.
33. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, Liao JK. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999;285:1276-1279.
34. Moghaddam MF, Grant DF, Cheek JM, Greene JF, Williamson KC, Hammock BD. Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase. Nat Med 1997;3:562-566.
35. Kundu S, Roome T, Bhattacharjee A, Carnevale KA, Yakubenko VP, Zhang R, Hwang SH, Hammock BD, Cathcart MK. Metabolic projects of soluble epoxide hydrolase are essential for monocyte chemotaxis to MCP-1 in vitro and in vivo. J Lipid Res 2013;54:436-447.
36. Hallstrand TS, Henderson WR Jr. An update on the role of leukotrienes in asthma. Curr Opin Allergy Clin Immunol 2010;10:60-66.
37. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac RL. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002;196:1025-1037.
38. Rogerio AP, Haworth O, Croze R, Oh SF, Uddin M, Carlo T, Pfeffer MA, Priluck R, Serhan CN, Levy BD. Resolvin D1 and aspirin-triggered resolvin D1 promote resolution of allergic airways responses. J Immunol 2012;189:1983-1991.
39. Locksley RM. Asthma and allergic inflammation. Cell 2010;140:777-783.
40. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, O'Byrne PM. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985-993.
41. Jacobs ER, Zeldin DC. The lung HETEs (and EETs) up. Am J Physiol Heart Circ Physiol 2001;280:H1-H10.
42. Copas JL, Borgeat P, Gardiner PJ. The actions of 5-, 12-, and 15-HETE on tracheobronchial smooth muscle. Prostaglandins Leukot Med 1982;8:105-114.